natgillin/translations-raw huggingface dataset:
The incidence of congenital malformations after assisted reproduction techniques may be slightly higher than after spontaneous conceptions.
Ta nekoliko večja pogostost je verjetno povezana s karakteristikami bolnikov, ki se zdravijo za neplodnostjo (npr. starost ženske, karakteristike sperme), in z večjo pogostostjo večplodne nosečnosti po postopku oploditve z biomedicinsko pomočjo.
This slightly higher incidence is thought to be related to characteristics of the patients undergoing fertility treatment (e. g. age of the female, sperm characteristics) and to the higher incidence of multiple gestations after assisted reproduction techniques. The incidence of congenital malformations after assisted reproduction techniques using Orgalutran is not different from that after using other GnRH analogues in the course of assisted reproduction techniques.
Pogostost pojavljanja prirojenih nepravilnosti v razvoju raznih delov telesa po postopku oploditve z biomedicinsko pomočjo, pri kateri se je uporabilo zdravilo Orgalutran, ni drugačna od tistih, ki uporabljajo druge GnRH analoge v postopku oploditve z biomedicinsko pomočjo.
There is a slightly increased risk of extra-uterine pregnancy in women with damaged fallopian tubes.
Obstaja rahlo povečano tveganje za zunajmaternično nosečnost pri ženskah s prizadetimi jajcevodi.
The efficacy and safety of Orgalutran has not been established in women weighing less than 50 kg or more than 90 kg.
Učinkovitost in varnost zdravila Orgalutran še nista bili ugotovljeni pri ženskah s telesno maso manjšo od 50 kg ali večjo od 90 kg.
Pregnancy and breast-feeding Orgalutran should be used during controlled ovarian stimulation for assisted reproduction techniques (ART).
Nosečnost in dojenje Zdravilo Orgalutran lahko uporabite med nadzorovano stimulacijo jajčnikov pri postopkih oploditve z biomedicinsko pomočjo (ART - assisted reproduction techniques).
It should not be used during pregnancy and breast-feeding.
Ne smete ga uporabljati med nosečnostjo in dojenjem.
Driving and using machines The effects of Orgalutran on ability to drive and use machines have not been studied.
Vpliv na sposobnost upravljanja vozil in strojev Študije o vplivu na sposobnost vožnje in upravljanja s stroji niso bile izvedene.
HOW TO USE ORGALUTRAN
KAKO UPORABLJATI ZDRAVILO ORGALUTRAN
Always use Orgalutran exactly as your doctor has told you.
Pri uporabi zdravila natančno upoštevajte zdravnikova navodila.
Orgalutran is used as part of the treatment for assisted reproduction techniques (ART) including in- vitro fertilisation (IVF).
Zdravilo Orgalutran se uporablja kot del zdravljenja pri postopkih oploditve z biomedicinsko pomočjo (ART) ter in vitro oploditvi (IVF).
Ovarian stimulation with follicle stimulating hormone (FSH) may start at day 2 or 3 of your period.
Stimulacija jajčnikov s folikle stimulirajočim hormonom (FSH) se lahko prične na 2. ali 3. dan vaše menstruacije.
Orgalutran (0.25 mg) should be injected just under the skin once daily, starting on day 6 of FSH administration.
Zdravilo Orgalutran (0, 25 mg) je treba injicirati neposredno pod kožo enkrat dnevno, začenši na šesti dan zdravljenja z FSH.
Based on your response to FSH, your doctor may decide to start on another day.
Na podlagi vašega odziva na FSH se lahko vaš zdravnik odloči tudi, da bo z zdravljenjem začel kak drugi dan.
The time between two Orgalutran injections as well as the time between the last Orgalutran injection and hCG injection should not exceed 30 hrs, as otherwise a premature ovulation (i. e. release of egg cells) may occur.
Časovni razmik med dvema injekcijama zdravila Orgalutran kakor tudi časovni razmik med zadnjo injekcijo zdravila Orgalutran ter injekcijo hCG ne sme biti daljši od 30 ur, ker lahko v nasprotnem primeru nastopi prezgodnja ovulacija (npr. sprostitev jajčnih celic).
Orgalutran is supplied in pre-filled syringes and should be injected slowly, just under the skin, preferably in the upper leg.
17 Zdravilo Orgalutran je na voljo v napolnjenih injekcijskih brizgah in ga je treba injicirati počasi, tik pod kožo, najbolje v zgornji del noge.
16 Instructions for use
Navodila za uporabo
Preparing the injection site Wash your hands thoroughly with soap and water.
Priprava mesta injiciranja Roke si temeljito umijte z milom in vodo.
Swab the injection site with a disinfectant (for example alcohol) to remove any surface bacteria.
Mesto vboda očistite z razkužilom (na primer z alkoholom), da odstranite površinske bakterije s kože.
Clean about 5 cm (two inches) around the point where the needle will go in and let the disinfectant dry for at least one minute before proceeding.
Očistite približno pet centimetrov okoli mesta vboda in počakajte vsaj eno minuto, da se razkužilo posuši, preden postopek nadaljujete.
Inserting the needle Remove needle cover.
Vbod igle Odstranite zaščitni pokrovček z igle.
Insert the needle at the base of the pinched-up skin at an angle of 45° to the skin surface.
Potisnite iglo do konca v kožo, ki jo držite med prstoma, pod kotom 45° na površino kože.
Vary the injection site with each injection.
Pri vsakem injiciranju zamenjajte mesto vboda.
Checking the correct needle position Gently draw back the plunger to check if the needle is positioned correctly.
Preverjanje pravilne lege igle Previdno potegnite bat nazaj, da preverite, ali je igla v pravilni legi.
If this happens, do not inject Orgalutran, but remove the syringe, cover the injection site with a swab containing disinfectant and apply pressure; bleeding should stop in a minute or two.
Če se to zgodi, ne smete injicirati zdravila Orgalutran, ampak potegnite brizgo z iglo ven, pokrijte mesto vboda z blazinico, namočeno v razkužilo, in pritisnite.
Do not use this syringe and dispose of it properly.
Krvavitev naj bi se ustavila v minuti ali dveh.
Injecting the solution Once the needle has been correctly placed, depress the plunger slowly and steadily, so the solution is correctly injected and the skin tissues are not damaged.
Injiciranje raztopine Ko je igla enkrat pravilno vbodena, počasi in enakomerno potisnite bat, da bo raztopina pravilno injicirana in ne boste poškodovali kožnega tkiva.
Removing the syringe Pull the syringe out quickly and apply pressure to the site with a swab containing disinfectant.
Odstranjevanje brizge Hitro potegnite brizgo z iglo iz kože in pritisnite na mesto vboda z blazinico, namočeno v razkužilo.
If you use more Orgalutran than you should Contact your doctor.
Če ste uporabili večji odmerek zdravila Orgalutran, kot bi smeli Obvestite svojega zdravnika.
If you forget to use Orgalutran Do not inject a double dose to make up for a dose.
Če ste pozabili uporabiti zdravilo Orgalutran Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
If you are more than 6 hours late (so the time between two injections is longer than 30 hours) administer the dose as soon as possible, and contact your doctor for further advice.
Če ste zamudili več kot 6 ur (tako, da je časovni razmik med dvema odmerkoma več kot 30 ur), si čimprej injicirajte odmerek in se posvetujte s svojim zdravnikom.
Like all medicines, Orgalutran can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Orgalutran neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
The local reaction normally disappears within 4 hours of administration.
Pri približno 1 od 10 bolnikov lahko zdravilo Orgalutran povzroči lokalno kožno reakcijo na mestu injiciranja (predvsem pordelost, z oteklino ali brez), ki običajno izgine v 4 urah po injiciranju.
Very rarely, in less than 1 in 10.000 patients, more widespread possibly allergic reactions have been observed.
Zelo redko, pri manj kot 1 od 10. 000 bolnikov, so opažali bolj razširjene reakcije, ki bi lahko bile alergijske.
Undesirable effects which may occur are headache, nausea and malaise.
Neželeni učinki, ki se lahko pojavijo, so glavobol, slabost in občutek bolehnosti.
These effects occur in less than 1 in 100 patients.
Ti učinki se pojavljajo pri manj kot 1 od 100 bolnikov.
In addition, undesirable effects are reported which are known to occur with controlled ovarian hyperstimulation treatment (e. g. abdominal pain, ovarian hyperstimulation syndrome (OHSS), ectopic pregnancy and miscarriage (see the patient information leaflet of the FSH-containing preparation you are treated with).
18 (OHSS), ektopična nosečnost in splav (glejte navodilo za uporabo za FSH vsebujoče zdravilo, s katerim vas zdravijo).
17 Worsening of a pre-existing rash (eczema) has been reported in one subject after the first Orgalutran dose.
Pri enem bolniku so poročali o poslabšanju že obstoječega izpuščaja (ekcema) po prejemu prvega odmerka zdravila Orgalutran.
HOW TO STORE ORGALUTRAN
SHRANJEVANJE ZDRAVILA ORGALUTRAN
Keep out of the reach and sight of children Do not use Orgalutran after the expiry date which is stated on the carton and on the label after ‘ EXP :’.
Zdravila Orgalutran ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini, poleg oznake ‘ Uporabno do: ’.
Store in the original package, in order to protect from light.
Shranjujte ga v originalni ovojnini, da bo zaščiteno pred svetlobo.
What Orgalutran contains
Kaj vsebuje zdravilo Orgalutran
- The active substance is ganirelix (0.25 mg in 0.5 ml solution).
- Zdravilna učinkovina je ganireliks (0, 25 mg v 0, 5 ml raztopine).
The pH may have
- Pomožne snovi so ocetna kislina in manitol v vodi za injekcije. pH je lahko uravnan z
been adjusted with sodium hydroxide and acetic acid.
natrijevim hidroksidom in ocetno kislino.
The solution is sterile, ready for use and intended for subcutaneous administration.
Raztopina je sterilna, pripravljena za uporabo in namenjena za subkutano uporabo.
Organon, Kloosterstraat 6, Postbus 20, 5340 BH Oss, the Netherlands.
Organon, Kloosterstraat 6, Postbus 20, 5340 BH Oss, Nizozemska.
The medicine was to be used with prednisone or prednisolone (anti-inflammatory medicines) in patients who had failed to respond to other anti-cancer medicines, when their cancer had spread from the original site to other parts of the body (metastatic) and had been shown to be ‘ hormone-refractory’.
Zdravilo naj bi se uporabljalo s prednizonom ali prednizolonom (protivnetni zdravili) pri bolnikih, ki se niso odzvali na druga zdravila proti raku in pri katerih se je rak razširil iz izvornega mesta na druge dele telesa (metastatski) in se je izkazal kot hormonsko neodziven.
The active substance in Orplatna, satraplatin, is a cytotoxic (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group ‘ platinum compounds’.
Zdravilna učinkovina zdravila Orplatna, satraplatin, je citotoksik (zdravilo, ki ubija celice, ki se delijo, kot na primer rakave celice) iz skupine spojin, ki vsebujejo platino.
The main measure of effectiveness was ‘ progression-free survival’ (the time taken for the disease to get worse) as well as overall survival time.
Glavno merilo učinkovitosti je bil čas preživetja, v katerem bolezen ni napredovala (čas do poslabšanja bolezni) kot tudi skupni čas preživetja.
Progression-free survival was measured using a ‘ composite’ method, which means that there was more than one symptom that could be used as a measure.
Čas preživetja, v katerem bolezen ni napredovala, so merili s kombinirano metodo, kar pomeni, da so kot merilo uporabljali več kot en simptom.
Once the company has supplied responses to the questions, the CHMP reviews them and may, before
Potem ko CHMP izda svoje mnenje, navadno traja približno dva meseca, preden Evropska komisija dovoljenje odobri.
Based on the review of the data and the company’ s response to the CHMP’ s list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Orplatna could not have been approved for the treatment of metastatic hormone-refractory prostate cancer.
Na podlagi pregleda podatkov in odgovorov družbe na seznam vprašanj, ki jih je zastavil CHMP v času umika vloge, je imel Odbor zadržke in začasno menil, da zdravila Orplatna ni mogoče odobriti za zdravljenje hormonsko neodzivnega metastatskega raka prostate.
Therefore, at the time of the withdrawal, the CHMP’ s view was that a benefit of Orplatna had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
CHMP je zato v času umika menil, da koristi zdravila Orplatna niso bile zadostno dokazane in da kakršne koli koristi ne odtehtajo znanih tveganj.
EU Number EU/ 1/ 01/ 179/ 001
Številka EU EU/ 1/ 01/ 179/ 001
Invented name Osigraft
zaščiteno ime Osigraft
Strength 3.5 mg
jakost 3, 5 mg
Pharmaceutical form Powder for suspension for implantation
farmacevtska oblika Prašek za suspenzijo za vstavljanje
Route of administration Intraosseous use
pot uporabe Intaosalna uporaba
Packaging Vial (glass)
ovojnina Viala (steklena)
Content 1g
vsebina 1 g
Osigraft is a powder to be made up into a suspension for implantation.
Zdravilo Osigraft je prašek, namenjen za pripravo suspenzije za vsaditev.
Osigraft is used to repair fractures of the tibia (shin bone) that have not healed after at least nine months.
Zdravilo Osigraft se uporablja za zdravljenje zlomov golenice, ki se niso zacelili po najmanj devetih mesecih.
It is used in patients who have previously had an autograft (a bone graft taken from their own bone, usually the hip) that has failed or when such a graft is not possible.
Uporablja se pri bolnikih, ki so bili predhodno neuspešno zdravljeni z avtolognim presadkom (presadkom, pridobljenim iz njihove lastne kosti, običajno kolka), ali pri bolnikih, pri katerih avtologno presajanje ni izvedljivo.
Immediately before use, Osigraft is mixed with 2 to 3 ml of sodium chloride solution to make up a suspension that has the consistency of wet sand.
Neposredno pred uporabo se zdravilo Osigraft zmeša z 2 do 3 ml raztopine natrijevega klorida, s čimer dobimo suspenzijo s konsistenco mokrega peska.
This mixture is then placed by the surgeon directly at the fracture site in contact with the prepared broken bone ends.
To mešanico kirurg nato nanese neposredno na mesto zloma v stik s pripravljenimi konci zlomljene kosti.
The surrounding soft tissues, such as muscle and skin, are then closed around the implant.
Nato se okrog vsadka zaprejo obkostna mehka tkiva, kot so mišice in koža.
Generally, one vial is sufficient, but a further vial can be used if necessary.
V splošnem zadošča ena viala, vendar pa je po potrebi mogoče uporabiti še eno vialo.
The active substance in Osigraft, eptotermin alfa, acts on the bone structure.
Zdravilna učinkovina zdravila Osigraft, eptotermin alfa, deluje na strukturo kosti.
It is a copy of protein called osteogenic protein 1, also known as bone morphogenetic protein 7 (BMP-7), that is produced naturally by the body and which helps the formation of new bone tissue.
Učinkovina je kopija proteina, imenovanega osteogeni protein 1, znan tudi kot kostni morfogenetski protein 7 (bone morphogenetic protein 7, BMP- 7), ki se naravno tvori v telesu in spodbuja tvorbo novega kostnega tkiva.
When implanted, eptotermin alfa stimulates the formation of new bone, helping to repair the broken bone.
Ko je vsajen, eptotermin alfa spodbuja tvorbo nove kosti, kar prispeva k celjenju zlomljene kosti.
Eptotermin alfa is produced by a method known as ‘ recombinant DNA technology’: it is made by cells that have received a gene (DNA), which makes them able to produce it.
Eptotermin alfa se proizvaja po metodi, imenovani „ tehnologija rekombinantne DNA “: tvorijo ga celice, ki so prejele gen (DNA), kar jim omogoča njegovo tvorjenje.
The replacement eptotermin alfa acts in same way as naturally produced BMP-7.
Nadomestni eptotermin alfa deluje na enak način kot naravno proizveden BMP- 7.
This was detected by looking at signs of repair of the fracture on an X-ray, whether the patient had any pain and was able to bear weight on the tibia, and whether there was any need for further treatment of the fractured tibia.
To so ugotavljali s preverjanjem znakov zacelitve zloma na rentgenski sliki ter ugotavljanjem, ali ima bolnik bolečine in ali lahko prenese težo na golenico, kakor tudi s preverjanjem, ali obstaja potreba po nadaljnjem zdravljenju zlomljene golenice.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has Osigraft shown during the studies?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Kakšne koristi je zdravilo Osigraft izkazalo med raziskavami?
Osigraft was at least as effective as bone autograft, the standard treatment.
Zdravilo Osigraft je bilo vsaj tako učinkovito kot avtologni presadek kosti, ki predstavlja standardno zdravljenje.
After nine months, 81% of the patients receiving Osigraft had responded to treatment (less pain and more weight bearing), compared with 77% of the patients treated with an autograft.
Po devetih mesecih se je na zdravljenje odzvalo 81% bolnikov, ki so prejeli zdravilo Osigraft (zmanjšanje bolečin in povečana zmožnost prenosa teže), v primerjavi s 77% bolnikov, ki so bili zdravljeni z avtolognim presadkom.
The most common side effects with Osigraft (seen in between 1 and 10 patients in 100) are erythema (redness), tenderness, swelling over the implant site, and heterotopic ossification (development of bone in abnormal areas) or myositis ossificans (abnormal bone growth in the muscle).
Najpogostejši neželeni učinki (opaženi pri 1 do 10 bolnikih izmed 100) so eritem (rdečica), občutljivost, zatekanje na mestu vsadka in heterotopična okostenitev (tvorba kosti zunaj mesta zloma) ali osificirajoči miozitis (nenormalna rast kosti v mišico).
For the full list of all side effects reported with Osigraft, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Osigraft, glejte Navodilo za uporabo.
Osigraft should also not be used by the following groups of patients: • skeletally immature (still growing), • with an autoimmune disease (where the immune system attacks parts of the body), • with an active infection at the surgery site or another serious infection, • without enough skin or blood supply at the fracture site, • where the fracture is disease-related (such as metabolic bone disease or cancer), • with have a tumour near the fracture, • receiving chemotherapy, radiation treatment or immunosuppression.
Zdravila Osigraft prav tako ne smejo uporabljati bolniki: • z nezrelim okostjem (ki še rastejo); • ki imajo znano avtoimunsko bolezen (ko imunski sistem napada dele telesa); • z aktivno okužbo na območju operacije ali drugo resno okužbo; • pri katerih mesto zloma ni ustrezno pokrito s kožo ali dovolj prekrvavljeno; • pri katerih je zlom povezan z boleznijo (npr. presnovnimi boleznimi kosti ali rakom); • ki imajo tumor v bližini mesta zloma; • ki prejemajo kemo -, radio - ali imunosupresivno terapijo.
The Committee for Medicinal products for Human Use (CHMP) decided that Osigraft’ s benefits are greater than its risks for the treatment of nonunion of tibia of at least nine month duration, secondary to trauma, in skeletally mature patients, where previous treatment with autograft has failed or use of autograft is unfeasible.
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Osigraft pri zdravljenju nezraslega zloma golenice, ki traja vsaj 9 mesecev, po telesni poškodbi, pri bolnikih z zrelim okostjem, v primerih, ko predhodno zdravljenje z avtolognim presadkom ni uspelo oziroma avtologno presajanje ni izvedljivo, večje od z njim povezanih tveganj.
The Committee recommended that Osigraft be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo Osigraft podeli dovoljenje za promet z zdravilom.
Other information about Osigraft:
Druge informacije o zdravilu Osigraft:
The European Commission granted a marketing authorisation valid throughout the European Union for Osigraft to Howmedica International S. de R.
Evropska komisija je dovoljenje za promet z zdravilom Osigraft, veljavno po vsej Evropski uniji, podelila družbi Howmedica International S. de R.
L. on 17 May 2001.
L. dne 17. maja 2001.
The marketing authorisation was renewed on 17 May 2006.
Dovoljenje za promet z zdravilom je bilo podaljšano 17. maja 2006.
The full EPAR for Osigraft is available here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Osigraft je na voljo tukaj.
Osigraft 3.3 mg, powder for suspension for implantation
Osigraft 3, 3 mg, prašek za suspenzijo za vstavljanje
* Human Osteogenic protein produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology
Vsaka viala vsebuje 1 g praška s 3, 3 mg eptotermina alfa * * Človeški osteogeni protein pridobljen iz celic jajčnikov kitajskega hrčka (Chinese Hamster Ovary – CHO) s tehnologijo rekombinantne DNA.
Powder for suspension for implantation.
Prašek za suspenzijo za vstavljanje.
Osigraft is a white to off-white granular powder.
Osigraft je bel ali belkast zrnast prašek.
Treatment of nonunion of tibia of at least 9 month duration, secondary to trauma, in skeletally mature patients, in cases where previous treatment with autograft has failed or use of autograft is unfeasible.
Zdravljenje nezraslega zloma golenice, ki traja vsaj 9 mesecev, po telesni poškodbi, pri bolnikih z zrelim okostjem, v primerih, ko predhodno zdravljenje z avtolognim presadkom ni uspelo ali avtologno presajanje ni izvedljivo.
Osigraft should be used by an appropriately qualified surgeon.
Osigraft lahko uporabljajo le ustrezno usposobljeni kirurgi.
Treatment requires a single surgery.
Zdravljenje zahteva eno samo operacijo.
Depending on the size of the defect, more than a single 1 g vial of Osigraft may be required.
Morda bo potrebna več kot ena 1 g viala Osigrafta, odvisno od velikosti poškodbe.
The maximum human dose should not exceed 2 vials since efficacy in the treatment on non-unions with gaps requiring higher doses has not been established.
Največji odmerek pri človeku ne sme presegati 2 vial, ker učinkovitost zdravljenja nezraslih zlomov z razpokami, za katere so potrebni višji odmerki, ni bila potrjena.
Osigraft is contraindicated in children (see section 4.3).
Osigraft je kontraindiciran pri otrocih (glejte poglavje 4. 3).
Osigraft is administered by direct surgical placement at the defect site in contact with the prepared bone surface.
Osigraft se uporablja z neposrednim kirurškim nanosom na mesto poškodbe v stiku s pripravljeno površino kosti.
Experience from controlled clinical trials is limited to stabilisation of the fracture site using concomitant intramedullary nailing.
Izkušnje iz nadzorovanih kliničnih raziskav so omejene na stabilizacijo mesta zloma s sočasno intramedularno učvrstitvijo z vijaki.
Aligning your thumb with the internal gap of the stopper, pry up the edge of the stopper.
Ko sprostite vakuum, 3. odstranite zamašek viale.
Once the vacuum is broken, remove the vial stopper while holding the vial upright to prevent loss of Osigraft.
Vialo pri tem držite pokonci, da bi preprečili izgubo Osigrafta.
2 Do not insert a needle through the stopper.
2 Ne vstavljajte igle skozi zamašek.
Puncture of the stopper with a needle may result in particles of stopper material contaminating the Osigraft.
Če zamašek prebodete z iglo, lahko delci njegovega materiala kontaminirajo Osigraft.
Reconstitute the product as explained in section 6.6.
Rekonstituirajte zdravilo, kot je opisano v poglavju 6. 6.
Debride fibrous, necrotic or sclerotic tissue and appropriately decorticate bone so that the reconstituted Osigraft is in direct contact with bleeding bone and viable osseous tissue.
Odstranite fibrozno, nekrotično ali sklerotično tkivo in ustrezno oluščite kost, tako da je rekonstituirani Osigraft v neposrednem stiku s krvavečo kostjo in živim kostnim tkivom.
Provide adequate haemostasis to ensure that Osigraft is not dislodged from the surgical site.
Poskrbite za ustrezno preprečitev krvavenja in tako zagotovite, da se Osigraft ne odstrani z 6. mesta operacije.